AR123701A1 - Preparación de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2 - Google Patents

Preparación de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2

Info

Publication number
AR123701A1
AR123701A1 ARP210102767A ARP210102767A AR123701A1 AR 123701 A1 AR123701 A1 AR 123701A1 AR P210102767 A ARP210102767 A AR P210102767A AR P210102767 A ARP210102767 A AR P210102767A AR 123701 A1 AR123701 A1 AR 123701A1
Authority
AR
Argentina
Prior art keywords
alkyl
independently selected
halogen
substituted
unsubstituted
Prior art date
Application number
ARP210102767A
Other languages
English (en)
Inventor
Yeon Lim
- Bao Jianming Hee
James P Roane
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR123701A1 publication Critical patent/AR123701A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se inventan compuestos de fórmula [1] y sales farmacéuticamente aceptables, ésteres y profármacos de los mismos, que son inhibidores de DGAT2. También se proporcionan métodos de preparación de compuestos de fórmula [1], composiciones farmacéuticas que comprenden compuestos de fórmula [1] y métodos de uso de estos compuestos para tratar la esteatosis hepática, esteatohepatitis no alcohólica (EHNA), fibrosis, diabetes mellitus de tipo 2, obesidad, hiperlipidemia, hipercolesterolemia, ateroesclerosis, declive cognitivo, demencia, enfermedades cardiorrenales tales como enfermedades renales crónicas e insuficiencia cardíaca y enfermedades y afecciones relacionadas, que comprenden administrar un compuesto de fórmula [1] a un paciente que lo necesita. Reivindicación 1: Un compuesto de fórmula [1], o una sal farmacéuticamente aceptable del mismo en donde: X, Y y Z se seleccionan independientemente entre N o C(R⁵); R¹ es (1) fenilo sin sustituir o sustituido con 1, 2 ó 3 R⁶, (2) heteroarilo de 5 ó 6 miembros que contiene 1, 2, 3 ó 4 heteroátomos seleccionados independientemente entre N, O y S, en donde el heteroarilo está sin sustituir o sustituido con 1, 2 ó 3 R⁶, o (3) heteroarilo condensado de 8 a 10 miembros que contiene 1, 2, 3 heteroátomos seleccionados independientemente entre N, O y S, en donde el heteroarilo está sin sustituir o sustituido con 1, 2 ó 3 R⁶; R²ᵃ y R²ᵇ se seleccionan independientemente entre (1) hidrógeno, (2) halógeno, (3) hidroxi, (4) alquilo (C₁₋₆), (5) haloalquilo (C₁₋₆), (6) R²ᵃ y R²ᵇ se unen para formar espirocicloalquilo (C₃₋₈) sin sustituir u opcionalmente monosustituido, disustituido con alquilo C₁₋₃, halógeno, OH, o (7) R²ᵃ y R²ᵇ se unen para formar espiro heterociclilo de 4 a 8 miembros que contiene 1 ó 2 heteroátomos seleccionados independientemente entre N, O y S en donde el heterociclilo está sin sustituir o sustituido con 1, 2 ó 3 R⁷; R³ es (1) heterociclilo de 4 a 7 miembros que contiene 1, 2 ó 3 heteroátomos seleccionados independientemente entre N, O y S, (2) heteroarilo de 5 ó 6 miembros que contiene 1, 2 ó 3 heteroátomos seleccionados independientemente entre N, O y S, (3) -alquil (C₁₋₆)-heteroarilo, en donde el heteroarilo es un heteroarilo de 5 ó 6 miembros que contiene 1, 2 ó 3 heteroátomos seleccionados independientemente entre N, O y S, (4) -alquil (C₁₋₆)-arilo, (5) -alquil (C₁₋₆)-heterociclilo, en donde el heterociclilo es un anillo de 3 a 6 miembros que contiene 1 ó 2 heteroátomos seleccionados independientemente entre N, O y S, (6) -alquilo (C₁₋₆), (7) -cicloalquilo (C₃₋₆), (8) -hidroxialquilo (C₁₋₆), (9) -alquil (C₁₋₆)-S(O)₂-NR⁸ᵃR⁸ᵇ, o (10) -alquil (C₁₋₆)-S(O)₂-alquilo (C₁₋₃), en donde cada cicloalquilo o heterociclilo está sin sustituir o sustituido con 1, 2 ó 3 R⁹, y en donde cada alquilo, arilo o heteroarilo está sin sustituir o sustituido con 1, 2 ó 3 R¹⁰; R⁴ es (1) hidrógeno, (2) alquilo (C₁₋₃), o R³ y R⁴ se combinan junto con el átomo de nitrógeno al que están unidos para formar un anillo heterociclilo mono- o bicíclico que contiene 1 ó 2 heteroátomos seleccionados independientemente entre N, O y S, en donde el anillo heterociclilo está sin sustituir o sustituido con 1, 2 ó 3 R¹¹; cuando está presente, cada R⁵ se selecciona entre (1) hidrógeno, (2) alquilo (C₁₋₃), (3) haloalquilo (C₁₋₃), (4) ciano, o (5) halógeno; cuando está presente, cada R⁶ se selecciona independientemente entre (1) ciano, (2) halógeno, (3) -O-alquilo C₁₋₆, (4) cicloalquilo (C₃₋₆), opcionalmente sustituido con halógeno u OH, (5) -(C=O)NH₂, (6) cicloalquiloxi (C₃₋₆) en donde el cicloalquilo está opcionalmente sustituido con halógeno u OH, (7) hidroxi, (8) -NR¹¹R¹¹, (9) -NH(C=O)alquilo (C₁₋₆), (10) amina cíclica (C₂₋₆), opcionalmente sustituida con uno o dos sustituyentes halógeno, (11) haloalquil (C₁₋₆)-, (12) O-haloalquil (C₁₋₆)- opcionalmente sustituido con OH, (13) -O-alquil (C₀₋₃)-cicloalquilo (C₃₋₆) opcionalmente sustituido con uno o dos halógeno, (14) -SO₂alquilo (C₁₋₆), (15) -SO₂NHalquilo (C₁₋₆), (16) -S-alquilo C₁₋₆, (17) -S-haloalquilo C₁₋₆, o (18) alquilo (C₁₋₆); cuando está presente, cada R⁷ se selecciona independientemente entre (1) alquilo (C₁₋₃), (2) halógeno, (3) alcoxi (C₁₋₃)-, (4) haloalquil (C₁₋₃)-, o (5) hidroxi; cuando están presentes, R⁸ᵃ y R⁸ᵇ se seleccionan independientemente entre (1) hidrógeno, (2) alquilo (C₁₋₃), o (3) cicloalquilo (C₃₋₇); cuando está presente, cada R⁹ se selecciona independientemente entre (1) alquilo (C₁₋₃), (2) haloalquil (C₁₋₃)-, (3) oxo, (4) cicloalquilo (C₃₋₆), (5) -N(R¹¹)₂, (6) hidroxi, (7) alcoxil (C₁₋₃)-, (8) ciano, (9) halógeno, (10) -SO₂alquilo (C₁₋₆), (11) -alquil (C₁₋₆)-SO₂alquilo (C₁₋₆), (12) -C(O)alquilo (C₁₋₃), o (13) O-alquilo (C₁₋₃); cuando está presente, R¹⁰ se selecciona independientemente entre (1) hidrógeno, (2) alquilo (C₁₋₃), (3) alcoxi (C₁₋₃)-, (4) hidroxi, (5) halógeno, (6) alquil (C₁₋₃)-S-, (7) haloalquil (C₁₋₃)-, o (8) N(R¹¹)₂; R¹¹, cuando está presente, es independientemente (1) hidrógeno, o (2) alquilo (C₁₋₃).
ARP210102767A 2020-10-08 2021-10-06 Preparación de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2 AR123701A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063089063P 2020-10-08 2020-10-08

Publications (1)

Publication Number Publication Date
AR123701A1 true AR123701A1 (es) 2023-01-04

Family

ID=78709520

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102767A AR123701A1 (es) 2020-10-08 2021-10-06 Preparación de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2

Country Status (20)

Country Link
US (3) US12410159B2 (es)
EP (1) EP4225735A1 (es)
JP (1) JP7482324B2 (es)
KR (1) KR102993831B1 (es)
CN (1) CN116457346A (es)
AR (1) AR123701A1 (es)
AU (1) AU2021358946A1 (es)
CA (1) CA3195032A1 (es)
CL (1) CL2023000978A1 (es)
CO (1) CO2023004366A2 (es)
CR (1) CR20230160A (es)
DO (1) DOP2023000068A (es)
EC (1) ECSP23034049A (es)
IL (1) IL301799A (es)
JO (1) JOP20230071A1 (es)
MX (1) MX2023003844A (es)
PE (1) PE20240217A1 (es)
TW (1) TW202229232A (es)
WO (1) WO2022076496A1 (es)
ZA (1) ZA202304150B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4532496A1 (en) * 2022-06-03 2025-04-09 Domain Therapeutics Novel par-2 inhibitors
AU2023400409A1 (en) 2022-12-02 2025-06-26 Merck Sharp & Dohme Llc Preparation of fused azole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors
CN117567352A (zh) * 2023-11-24 2024-02-20 云南省烟草公司楚雄州公司 一种吲哚酮的合成方法
WO2026096330A1 (en) 2024-10-28 2026-05-07 Merck Sharp & Dohme Llc Glp-1 receptor agonists and methods of use

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
AU6691798A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
DE69819311T2 (de) 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
CZ297264B6 (cs) 1998-09-09 2006-10-11 Metabasis Therapeutics, Inc. Nové heteroaromatické inhibitory fruktóza-1,6-bisfosfatázy
CA2415742A1 (en) 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
US6852738B2 (en) 2001-01-30 2005-02-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
EP1455815A4 (en) 2001-12-19 2006-11-02 Millennium Pharm Inc MEMBERS OF THE DIACYLGLYCEROL-ACYLTRANSFERASES FAMILY 2 (DGAT2) AND USES THEREOF
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
CA2495943C (en) 2002-08-29 2009-07-21 Merck & Co., Inc. Indoles having anti-diabetic activity
WO2004019869A2 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
CA2512879A1 (en) 2003-01-17 2004-08-12 Soumya P. Sahoo N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
US20080287479A1 (en) 2006-12-20 2008-11-20 Pfizer Inc Inhibitors of serine palmitoyltransferase
EP2174343A1 (en) 2007-06-28 2010-04-14 Semiconductor Energy Laboratory Co, Ltd. Manufacturing method of semiconductor device
US20100179173A1 (en) 2007-06-28 2010-07-15 Daniel Guay Substituted fused pyrimidines as antagonists of gpr105 activity
US20110301079A1 (en) 2007-09-21 2011-12-08 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Neuromedin u receptor agonists and uses thereof
EP2367817A4 (en) * 2008-12-03 2012-05-09 Via Pharmaceuticals Inc INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE
WO2010077839A1 (en) * 2008-12-15 2010-07-08 Wyeth Llc (Formerly Known As Wyeth) Substituted oxindol cb2 agonists for pain treatment
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
AU2013245353A1 (en) 2012-04-06 2014-09-25 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors
AR098394A1 (es) 2013-11-25 2016-05-26 Lilly Co Eli Inhibidores de dgat2 (diacilglicerol o-aciltransferasa 2)
US9669624B2 (en) 2013-11-26 2017-06-06 Hewlett-Packard Development Company, L.P. Fluid ejection apparatus with single-side thermal sensor
CU24395B1 (es) 2014-03-17 2019-04-04 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
US10568876B2 (en) 2014-09-05 2020-02-25 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
EP3188730B1 (en) 2014-09-05 2019-05-01 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
WO2016036638A1 (en) 2014-09-05 2016-03-10 Merck Sharp & Dohme Corp. Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
CA2991894A1 (en) 2015-07-10 2017-01-19 Ionis Pharmaceuticals, Inc. Modulators of diacyglycerol acyltransferase 2 (dgat2)
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
RU2019117556A (ru) 2016-11-18 2020-12-18 Мерк Шарп И Доум Корп. Индазольные производные, пригодные в качестве ингибиторов диацилглицерид o-ацилтрансферазы 2
CN109963561A (zh) * 2016-11-18 2019-07-02 默沙东公司 可用作二酰基甘油酯o-酰基转移酶2的抑制剂的吲哚衍生物
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
WO2021127443A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
AU2021356589A1 (en) 2020-10-08 2023-05-25 Merck Sharp & Dohme Llc Preparation of benzimidazolone derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors
EP4225753B1 (en) 2020-10-08 2024-07-31 Leukos Biotech, S.L. Potent and selective compounds as serotonin 1b receptor modulators
US11541039B2 (en) 2020-10-08 2023-01-03 Endogena Therapeutics, Inc. Compounds and their use as therapeutically active substances in the treatment and/or reducing signs or symptoms of diseases involving the retinal pigment epithelium

Also Published As

Publication number Publication date
AU2021358946A1 (en) 2023-06-08
ECSP23034049A (es) 2023-06-30
JOP20230071A1 (ar) 2023-04-06
DOP2023000068A (es) 2023-05-31
PE20240217A1 (es) 2024-02-16
TW202229232A (zh) 2022-08-01
US12428411B2 (en) 2025-09-30
CN116457346A (zh) 2023-07-18
IL301799A (en) 2023-05-01
CO2023004366A2 (es) 2023-04-27
MX2023003844A (es) 2023-04-14
ZA202304150B (en) 2024-12-18
WO2022076496A1 (en) 2022-04-14
EP4225735A1 (en) 2023-08-16
CR20230160A (es) 2023-06-02
US20220112181A1 (en) 2022-04-14
AU2021358946A9 (en) 2024-02-08
JP2023541714A (ja) 2023-10-03
JP7482324B2 (ja) 2024-05-13
CL2023000978A1 (es) 2023-09-29
US20240327391A1 (en) 2024-10-03
KR20230079427A (ko) 2023-06-07
KR102993831B1 (ko) 2026-07-23
CA3195032A1 (en) 2022-04-14
US20260234134A1 (en) 2026-08-13
US12410159B2 (en) 2025-09-09

Similar Documents

Publication Publication Date Title
PE20251288A1 (es) Compuestos heterociclicos como inmunomoduladores
AR091654A1 (es) COMPUESTOS QUE CONTIENEN BIARILO COMO AGONISTAS INVERSOS DE RECEPTORES ROR-g
AR118374A1 (es) Inhibidores de la proteína tirosina fosfatasa y métodos para usarlos
AR117139A1 (es) Derivados de piridooxazinona como inhibidores de monoacilglicerol ligasa (magl)
AR113964A1 (es) Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa
AR110139A1 (es) COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV
AR112834A1 (es) Derivados de rapamicina
AR107714A1 (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
AR090945A1 (es) Moduladores de la via del complemento y usos de los mismos
AR122092A1 (es) Inhibidores de diacilglicerol o-aciltransferasa 2
AR054090A1 (es) Derivados de quinuclidina como antagonistas del receptor muscarinico m3. composiciones farmaceuticas y proceso de obtencion
AR118050A1 (es) Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
AR111874A1 (es) Derivados de pirimidina
AR120652A1 (es) Antagonistas de sstr5
AR121554A1 (es) Azálidos de urea inmunoduladores
AR121299A1 (es) Inhibidores heterocíclicos de pad4
AR100714A1 (es) Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor
AR124189A1 (es) Compuestos y procedimientos de uso de los mismos
AR123700A1 (es) Preparación de derivados de benzoimidazolona como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2
AR114564A1 (es) DERIVADOS DE 2,4,6,7-TETRAHIDRO-PIRAZOLO[3,4-D]PIRIMIDIN-ONA COMO MODULADORES DEL RECEPTOR C5a Y COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDE
CR20230160A (es) Preparación de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2
AR124303A1 (es) Inhibidores de irak4
CO6341621A2 (es) Piperidinas arilamino y heteroarilamino sustituidas como inhibidores de glyt-1
AR118641A1 (es) Compuestos, composiciones y métodos
AR120170A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4